CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
接受 CAR-T 细胞治疗的复发/难治性 B 细胞淋巴瘤患者的适应性桥接放疗：病例报告
英文原题：Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case report.
查看英文原题
Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
放射治疗（RT）被用作侵袭性B细胞淋巴瘤患者在接受CD19靶向嵌合抗原受体（CAR-T）细胞治疗前的桥接策略。RT已被证明能够提供局部控制，且不会加重后续CAR-T 细胞输注相关的毒性。然而，关于桥接目的的最佳放射剂量和分割方案尚未达成共识。我们报告了一例复发性侵袭性B细胞淋巴瘤患者，在接受CAR-T 细胞治疗前于CT-linac上接受了桥接适应性RT。CAR-T 输注后第6个月，患者未表现出疾病复发或复发的迹象，也未出现可归因于联合治疗的任何意外毒性。这凸显了该创新方法在治疗接受CAR-T 细胞治疗的淋巴瘤患者中的可行性和成功。
展开英文摘要原文
Radiation therapy (RT) is utilized as a bridging strategy for patients with aggressive B-cell lymphoma prior to CD19-targeted chimeric antigen receptor (CAR T)-cell therapy. RT has been shown to provide local control without exacerbating the toxicities associated with subsequent CAR T-cell infusion.
However, a consensus on the optimal radiation dose and fractionation for bridging purposes has yet to be established.
We present a case of a patient with relapsed aggressive B-cell lymphoma who underwent bridging adaptive RT on a CT-linac prior to receiving CAR T-cell therapy. At month 6 post-CAR T infusion, the patient demonstrates no signs of disease recurrence or relapse, nor any unexpected toxicities attributable to the combined treatment. This underscores the feasibility and success of this innovative approach in treating lymphoma patients undergoing CAR T-cell therapy.
论文信息
- 作者
- Ababneh HS、Connor Johnson P、Pursley J、Patel CG
- 单位
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.United States
- 文献类型
- 病例报告
- 期刊
- Clinical and translational radiation oncology2024 Sep
- 原文标识
- PubMed 39185000 · DOI 10.1016/j.ctro.2024.100832
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →